AzTrials
AzTrials

Out-of-hospital Cardiac ArrestPhase 4NCT02899507

Prophylactic Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest

A Phase 4 study testing Amoxicillin-Clavulanic acid in people with Out-of-hospital Cardiac Arrest, run by University Medical Centre Ljubljana at 1 site in Slovenia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether there is potential benefits of prophylactic antibiotic treatment in comatose survivors of out-of-hospital cardiac arrest (OHCA) treated in intensive care unit with therapeutic hypothermia. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Out-of-hospital Cardiac Arrest
What is being tested?
Amoxicillin-Clavulanic acid
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteSlovenia
Study dates
Sep 2013to Apr 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Female and male over 18 years old
  • Comatose survivors of out-of-hospital cardiac arrest treated in intensive care unit with therapeutic hypothermia

Who cannot join

  • Suspected or confirmed pregnancy
  • Allergy to amoxicillin-clavulanic acid
  • Tracheobronchial aspiration
  • Antibiotic therapy before cardiac arrest
  • Need of antibiotics due to other causes
  • Candidates for immediate veno-arterial extracorporeal membrane oxygenation (VA ECMO)
  • Patients in whom no active treatment was decided on admission

Trial locations and contacts

1 site in 1 country.

Slovenia1 site
  • University Medical Centre Ljubljana

    Ljubljana, 1000

Other trials in Slovenia

About this study

Official title: Prophylactic Versus Clinically-driven Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest

The purpose of this study is to determine whether there is potential benefits of prophylactic antibiotic treatment in comatose survivors of out-of-hospital cardiac arrest (OHCA) treated in intensive care unit with therapeutic hypothermia.

Read the detailed description

Postresuscitation management of comatose survivors of out-of-hospital cardiac arrest (OHCA) significantly improved and "bundle of care" including therapeutic hypothermia, immediate coronary angiography, percutaneous coronary intervention (PCI) and contemporary intensive care nowadays leads to survival with good neurological recovery. Benefit of prophylactic antibiotics, which may suppress development of postresuscitation infection and especially early onset pneumonia and thereby decrease the severity of postresuscitation systemic inflammatory response, is controversial. Because of these uncertainties, the investigators performed a single-center randomized clinical trial comparing prophylactic versus clinically-driven administration of antibiotics in comatose survivors of OHCA. The investigators hypothesized that prophylactic antibiotics may decrease the severity of postresuscitation systemic inflammatory response by reducing the incidence of postresuscitation infection and especially pneumonia which was further addressed by repeat microbiological sampling.

Being tested
Amoxicillin-Clavulanic acid
Keywords
Out-of-hospital cardiac arrest, Prophylactic antibiotics
Medical subject headings
Out-of-Hospital Cardiac Arrest

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Amoxicillin-Clavulanic acidDrug

    Also called Amoksiklav, Augmentin

    Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h

Study groups in NCT02899507
Study groupRoleWhat they receive
Prophylactic antibioticExperimentalAmoxicillin-Clavulanic acid 1.2g every 8h
Receives: Drug: Amoxicillin-Clavulanic acid
Clinically-driven antibioticsNo interventionAdministration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Value of C-reactive protein (CRP) at day three

    Expressed in milligram/litre (normal <5 mg/L)

    Measured: Three days after admission to Intensive care unit (ICU)

Secondary outcomes (10)
  1. Severity of systemic inflammatory response estimated by peak white blood cell count (WBC)

    Expressed in number of white blood cells x 109 per litre (L)

    Measured: First measurement at admission in hospital and afterwards in 24 hours intervals during stay in the intensive care unite (ICU) but not longer then first seven days

  2. Severity of systemic inflammatory response estimated by peak value of procalcitonin (PCT)

    Expressed in microgram/litre (normal <0.5 microgram/L)

    Measured: First measurement at admission in hospital and afterwards in 24 hours intervals during stay in the intensive care unite (ICU) but not longer then first seven days

  3. Severity of systemic inflammatory response estimated by peak value of neutrophil Cluster of differentiation 64 (CD 64)

    Neutrophil CD 64 expression was used as an index of sepsis with >1.2 indicating greater likelihood of sepsis

    Measured: First measurement at admission in hospital and afterwards in 24 hours intervals in the first three days

  4. Appearance of pneumonia on chest X ray

    Measured: Chest X ray was taken on admission and afterwards on daily basis during the stay in the intensive care unite but not longer than first week

  5. Incidence of positive blind mini bronchoalveolar lavage (Mini-BAL) on day 3

    Measured: Mini-BAL was performed on the third day after the sudden cardiac arrest

  6. Incidence of positive hemocultures

    Measured: From the admission until the patient was transferred to the ward. This was always during the ICU stay-one month

  7. Duration of tracheal intubation

    Duration of intubation was expressed as days of intubation started with admission until the extubation. Because this is being done in intensive care unite, the time frame is duration of ICU stay

    Measured: From the day of admission until the extubation. This was always during the ICU stay- one month

  8. Duration of mechanical ventilation

    Duration of mechanical ventilation was expressed as days the patient needed the mechanical support for breathing regardless of mode of support

    Measured: From the admission until spontaneous breathing . This was during ICU stay-one month

  9. ICU stay

    Measured: From the admission until the patient was transferred to ward, usually less than one month

  10. Survival with good neurological outcome

    Good neurological outcome was characterised using cerebral performance category (CPC) with 1-2 indicating good neurological recovery.

    Measured: Up to six months after the event

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2016 (estimated)
  2. Study startSep 2013
  3. Primary completionMar 2015
  4. Study completionApr 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02899507
Sponsor's protocol ID
P3-0331
Status last verified
Aug 2016
First submitted
30 Jun 2016
Last updated
14 Sep 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Tomte O, Andersen GO, Jacobsen D, Draegni T, Auestad B, Sunde K. Strong and weak aspects of an established post-resuscitation treatment protocol-A five-year observational study. Resuscitation. 2011 Sep;82(9):1186-93. doi: 10.1016/j.resuscitation.2011.05.003. Epub 2011 May 14.

    PubMed 21636202
  • Stub D, Hengel C, Chan W, Jackson D, Sanders K, Dart AM, Hilton A, Pellegrino V, Shaw JA, Duffy SJ, Bernard S, Kaye DM. Usefulness of cooling and coronary catheterization to improve survival in out-of-hospital cardiac arrest. Am J Cardiol. 2011 Feb 15;107(4):522-7. doi: 10.1016/j.amjcard.2010.10.011. Epub 2010 Dec 22.

    PubMed 21184989
  • Kocjancic ST, Jazbec A, Noc M. Impact of intensified postresuscitation treatment on outcome of comatose survivors of out-of-hospital cardiac arrest according to initial rhythm. Resuscitation. 2014 Oct;85(10):1364-9. doi: 10.1016/j.resuscitation.2014.06.028. Epub 2014 Jul 8.

    PubMed 25010782
  • Perbet S, Mongardon N, Dumas F, Bruel C, Lemiale V, Mourvillier B, Carli P, Varenne O, Mira JP, Wolff M, Cariou A. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1048-54. doi: 10.1164/rccm.201102-0331OC.

    PubMed 21816940
  • Mongardon N, Perbet S, Lemiale V, Dumas F, Poupet H, Charpentier J, Pene F, Chiche JD, Mira JP, Cariou A. Infectious complications in out-of-hospital cardiac arrest patients in the therapeutic hypothermia era. Crit Care Med. 2011 Jun;39(6):1359-64. doi: 10.1097/CCM.0b013e3182120b56.

    PubMed 21336107
  • Gajic O, Festic E, Afessa B. Infectious complications in survivors of cardiac arrest admitted to the medical intensive care unit. Resuscitation. 2004 Jan;60(1):65-9. doi: 10.1016/j.resuscitation.2003.08.005.

    PubMed 14987786
  • Woo JH, Lim YS, Yang HJ, Park WB, Cho JS, Kim JJ, Hyun SY, Lee G. Factors associated with pneumonia in post-cardiac arrest patients receiving therapeutic hypothermia. Am J Emerg Med. 2014 Feb;32(2):150-5. doi: 10.1016/j.ajem.2013.10.035. Epub 2013 Oct 26.

    PubMed 24268585
  • Ribaric SF, Turel M, Knafelj R, Gorjup V, Stanic R, Gradisek P, Cerovic O, Mirkovic T, Noc M. Prophylactic versus clinically-driven antibiotics in comatose survivors of out-of-hospital cardiac arrest-A randomized pilot study. Resuscitation. 2017 Feb;111:103-109. doi: 10.1016/j.resuscitation.2016.11.025. Epub 2016 Dec 14.

    PubMed 27987397

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Amoxicillin-Clavulanic acid in people with Out-of-hospital Cardiac Arrest, run by University Medical Centre Ljubljana at 1 site in Slovenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Value of C-reactive protein (CRP) at day three (time frame: Three days after admission to Intensive care unit (ICU)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02899507, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in